Showing 1421-1430 of 3103 results for "".
- Database of Eye-Tracking Movements Could Aid Diagnosis and Treatmenthttps://practicalneurology.com/news/database-of-eye-tracking-movements-could-aid-diagnosis-and-treatment/2468784/Eye-tracking technology (Brain Health EyeQ; RightEye, Bethesda, MD) that captures data on people’s eye movements has been used to produce a database of 1 billion data points from 100,000 individuals. Data includes eye tracking measures of alignment, object tracking, depth perception, and dy
- FDA Provides Expanded Clearance for Device to Treat Migraine in Childrenhttps://practicalneurology.com/news/fda-provides-expanded-clearance-for-device-to-treat-migraine-in-children/2468822/The Food and Drug Administration (FDA) has granted new marketing clearance for a device that provides acute and preventive treatment of migraine to include children 12 years of age and older. The technology (sTMS; eNeura, Inc., Baltimore, MD) is a non-invasive device that uses single-puls
- FDA Greenlights Phase 2a Trial of Intranasal Foralumab in Multiple System Atrophyhttps://practicalneurology.com/news/fda-greenlights-phase-2a-trial-of-intranasal-foralumab-in-multiple-system-atrophy/2476103/The Food and Drug Administration (FDA) has approved an Investigational New Drug (IND) application, permitting the evaluation of treatment with intranasal foralumab (Tiziana Life Sciences, New York, NY) for people with multiple system atrophy (MSA) in a phase 2a clinical trial (NCT06868628). MSA i
- Cell Therapy for ALS Associated with Increased Survival at 5 Yearshttps://practicalneurology.com/news/cell-therapy-for-als-shows-promise-in-increasing-survival-at-five-years/2475217/Nine out of 10 people with amyotrophic lateral sclerosis (ALS) treated with NurOwn (autologous mesenchymal stem cells [MSC]–neurotrophic factors [NTF]; BrainStorm Cell Therapeutics, New York, NY) survived more than 5 years after symptom onset. These results from an analysis of survival data from
- New Technology May Help Differentiate Between Parkinsonismshttps://practicalneurology.com/news/new-technology-may-help-differentiate-between-parkinsonisms/2473819/A machine learning–based software tool (neuropacs; Gainesville, FL) analyzing 3T diffusion MRI scans was found to be effective in distinguishing between Parkinson disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP) in people with diagnosed movement disorder
- Stem Cell Therapy Reduced Brain Atrophy in People with Mild Alzheimer Diseasehttps://practicalneurology.com/news/stem-cell-therapy-reduced-brain-atrophy-in-people-with-mild-alzheimer-disease/2473818/The intravenous (IV) treatment of people with mild Alzheimer disease (AD) using Lomecel-B (laromestrocel; Longeveron, Miami, FL), a bone-marrow–derived allogeneic mesenchymal stem cell (MSC), was associated with reduced atrophy of the whole brain and hippocampus compared with placebo. These
- FDA Grants Fast Track Designation to Potential Treatment for Multiple System Atrophyhttps://practicalneurology.com/news/fda-grants-fast-track-designation-to-potential-treatment-for-multisystem-atrophy/2473790/Amlenetug (Lundbeck, Deerfield, IL), a monoclonal antibody (mAb) that targets extracellular α-synuclein, was granted Fast Track Designation (FTD) by the Food and Drug Administration (FDA) for investigation as a potential treatment for multiple system atrophy (MSA). According to a statement
- Phosphorylated α-Synuclein Detectable by Skin Biopsy in Those with Synucleionopathies Including Parkinson Diseasehttps://practicalneurology.com/news/phosphorylated-a-synuclein-detectable-by-skin-biopsy-in-those-with-synucleionopathies-including-parkinson-disease/2470436/According to study results published in JAMA, a high proportion of people with Parkinson disease (PD), multiple system atrophy (MSA), dementia with Lewy bodies (DLB), and pure autonomic failure (PAF) showed skin biopsies positive for cutaneous phosphorylated α-synuclein. The result
- Ampreloxetine May Be Effective at Treating Neurogenic Orthostatic Hypotension in Patients with Multiple System Atrophyhttps://practicalneurology.com/news/ampreloxetine-may-be-effective-at-treating-neurogenic-orthostatic-hypotension-in-patients-with-multiple-system-atrophy/2470280/Ampreloxetine (Theravance Biopharma, South San Francisco, CA) may be a safe and effective treatment for symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA) according to study results presented at the 2023 International Congress of Parkinson’s
- FDA Issues Refusal To File Letter for New Biologics License Application for Stem Cell ALS Treatmenthttps://practicalneurology.com/news/fda-does-not-file-new-biologics-license-application-for-stem-cell-amyotrophic-lateral-sclerosis-treatment/2470068/The Food and Drug Administration (FDA) has issued a refusal to file letter for the Biologics License Application (BLA) for autologous neurotrophic factor-secreting mesenchymal stem cells (MSC-NTF)(NurOwn; BrainStorm Cell Therapeutics, New York, NY) as treatment of amyotrophic lateral sclerosis (A